Table 1

Baseline characteristics of patients with COVID-19 with new onset of CVD during infection

	Type of CVD	Subtype of AIS	Age (years)	Sex	Smoking history	Drinking history	Blood pressure (mm Hg)	Blood glucose (mmol/L)	Type of patients with COVID-19 (severe/non-severe)	Time between onset of SARS-CoV-2 infection and onset of CVD in days	NIHSS score of AIS onset	Treatment of CVD	Outcome event
1	AIS	Large-vessel atherosclerosis	70s	F	No	No	110/67	6.0	Severe	23	3	Antiplatelet	Survival
2	AIS	Small-vessel occlusion	70s	M	No	No	110/70	5.4	Severe	29	3	Antiplatelet	Survival
3	AIS	Large-vessel atherosclerosis	50s	M	No	No	127/83	13.2	Non-severe	1	4	Antiplatelet	Survival
4	AIS	Cardioembolism	80s	M	Yes	No	110/72	13.8	Severe	19	8	Antiplatelet	Death
5	AIS	Large-vessel atherosclerosis	80s	F	No	No	140/83	24.2	Severe	15	20	Antiplatelet	Death
6	AIS	Small-vessel occlusion	70s	M	Yes	No	156/82	11.0	Severe	1	2	Antiplatelet	Death
7	AIS	Cardioembolism	80s	F	No	No	97/64	6.8	Non-severe	1	23	Anticoagulant	Death
8	AIS	Large-vessel atherosclerosis	90s	F	No	No	192/97	6.7	Severe	10	28	Anticoagulant	Survival
9	AIS	Large-vessel atherosclerosis	70s	F	No	No	155/89	7.9	Severe	12	18	Anticoagulant	Survival
10	AIS	Cardioembolism	70s	M	Yes	No	142/67	16.3	Severe	8	35	Anticoagulant	Death
11	ICH		60s	M	Yes	Yes	150/80	5.8	Severe	10			Death

*Patients with COVID-19 were confirmed by SARS-CoV-2 reverse transcription-PCR positive in throat swab and viral-like pneumonia in chest CT.
AIS, acute ischemic stroke; CVD, cerebrovascular disease; CVST, cerebral venous sinus thrombosis; F, female; ICH, intracerebral haemorrhage ; M, male; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TOAST, the Trial of Org 10 172 in Acute Stroke Treatment.